EPO pharma case law trends 2025: Antibodies and biologics

Antibodies and other biologics are challenging and expensive to develop. They can simultaneously be difficult to protect in view of strict and conflicting patentability requirements in the US and Europe. The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted